Humana · Hizentra CIDP · US health-plan appeal rights

Hizentra CIDP denied for failing step therapy by Humana?

Q: How long do I have to appeal a Humana Hizentra CIDP denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Humana typically requires

Humana's specific coverage criteria for hizentra cidp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Humana Hizentra (Immune Globulin Subcutaneous) for CIDP Maintenance

The Humana angle on Hizentra CIDP

## Why Humana Requires Step Therapy Before Hizentra for CIDP — and How to Appeal

A step-therapy denial means Humana requires documented use of one or more "preferred" treatments before approving Hizentra (subcutaneous immune globulin) for chronic inflammatory demyelinating polyneuropathy (CIDP). In practice this usually means the plan wants evidence that intravenous immunoglobulin (IVIG) or another designated first-step therapy was tried and either failed, caused adverse effects, or is clinically inappropriate for this patient.

### Why This Denial Is Appealable

Step-therapy protocols are not absolute. Federal and many state laws — including step-therapy override protections enacted in numerous states — require that a plan grant an exception when the required first-step therapy is contraindicated, has already been tried and failed, or when a treating specialist documents that the required step would cause foreseeable harm. Humana's own step-therapy exception policy, referenced in the denial letter, should outline the override pathway.

### Federal Appeal Rights

Internal appeal: Submit within the timeframe on the denial notice. Humana must decide within 30 days for standard pre-service appeals.
External review (ACA §2719 / ERISA §503): After a final internal denial you have independent external review rights, typically within a four-month filing window. An impartial reviewer — not employed by Humana — evaluates whether the step requirement is clinically appropriate for your specific case.
Expedited review: Available when the standard timeline poses a serious health risk; decisions typically required within 72 hours.

### Documentation to Gather

1. Prior IVIG or first-step therapy records: Dates of treatment, doses administered, documented response (or lack thereof), and any adverse events. If IVIG was administered in an infusion center, obtain those infusion records. 2. Reason for step failure or inapplicability: Specialist notes explaining why the required step therapy failed, caused intolerable side effects, or is medically contraindicated for this individual patient. 3. CIDP diagnosis confirmation: Neurology notes, electrodiagnostic reports, and clinical severity documentation. 4. Prescriber step-therapy exception letter: A detailed letter from the treating neurologist stating which step was attempted (or why it cannot be attempted), what outcome occurred, and why Hizentra is now the medically appropriate next step per current neurology guidelines and the FDA-approved label. 5. Applicable guideline reference: Note the relevant professional society guideline (e.g., the applicable neurology or immunology society guideline) that supports SCIG as an appropriate option for patients in this clinical situation, without quoting specific trial statistics.

### Criteria-Mapping Structure

Obtain Humana's current published coverage policy for Hizentra or subcutaneous immunoglobulin. List each step-therapy requirement. For each one, provide the chart evidence that either satisfies the step or documents a valid clinical reason to bypass it. A well-mapped appeal leaves no requirement unanswered and makes the reviewer's job straightforward.

Always verify the exact step-therapy criteria against Humana's current coverage policy and the FDA-approved Hizentra prescribing label for the plan year in question.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Humana appeals

Other denial reasons for Humana Hizentra CIDP

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.